NeOnc CEO Buys More Shares Below $5 as NTHI Secures FDA Meeting to Discuss Phase 3 Trial

Observed price moves

• NTHI+2.77%10 min after this headline

MoveSurge carries market-moving headlines the moment they reach the wire, each one with what the price did next.